Inovotion

Executive Summary

Inovotion is a French biotechnology company specializing in preclinical oncology and immuno-oncology services using its proprietary chicken egg chorioallantoic membrane (CAM) xenograft model. Founded in 2014 and headquartered in Grenoble with a US subsidiary in Cambridge, MA, the company offers unique in vivo efficacy and toxicity assays that aim to accelerate and de-risk drug discovery for pharmaceutical and biotech clients. By providing a rapid, cost-effective alternative to traditional mouse models, Inovotion addresses a critical bottleneck in early-stage drug development, particularly for oncology and cell therapy programs. The CAM model enables high-throughput screening of tumor response and compound toxicity, potentially reducing the time and cost of bringing new therapies to market. Inovotion's service-based business model positions it as a key partner for drug developers seeking to validate candidates before committing to expensive mammalian studies. While the company operates in a competitive landscape of CROs and academic labs, its proprietary technology and focus on the CAM model offer differentiation. The company has not disclosed funding or valuation details, suggesting it may be bootstrapped or in early growth stages. Future success depends on expanding its client base, demonstrating predictive validity of its assays, and possibly forming strategic partnerships with larger CROs or pharmaceutical companies. With oncology R&D spending growing, Inovotion is well-placed to capture a niche segment of the preclinical market.

Upcoming Catalysts (preview)

• Q4 2026Major partnership or collaboration with a top pharma or CRO30% success
• Q2 2027Expansion of service offerings to include immunotherapy or PDX models50% success
• Q3 2026Series A funding round or government grant announcement40% success